Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
14.80
-0.01 (-0.07%)
At close: Jul 2, 2026, 4:00 PM EDT
14.50
-0.30 (-2.03%)
After-hours: Jul 2, 2026, 7:47 PM EDT
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
95
Market Cap
201.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 72.66M |
| Arcturus Therapeutics Holdings | 54.71M |
| Precision BioSciences | 45.07M |
| Tonix Pharmaceuticals Holding | 17.56M |
| MediWound | 14.48M |
| Korro Bio | 3.84M |
| Humacyte | 2.02M |
| Oramed Pharmaceuticals | 2.00M |
IMUX News
- 25 days ago - Immunic to Participate in Investor, Industry and Scientific Conferences in June - PRNewsWire
- 4 weeks ago - Immunic Slides: Corporate presentation - Filings
- 5 weeks ago - Immunic Proxy statement: Proxy filing - Filings
- 5 weeks ago - Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - PRNewsWire
- 5 weeks ago - Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed - TheFly
- 5 weeks ago - Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer - PRNewsWire
- 6 weeks ago - B. Riley cuts Immunic target, sees ‘compelling entry point’ - TheFly
- 6 weeks ago - Immunic appoints Michael Bonney as chair - TheFly